Search results for " LDL"

showing 10 items of 454 documents

No Improvement of High-Density Lipoprotein (HDL) Vasorelaxant Effect Despite Increase in HDL Cholesterol Concentration in Type 2 Diabetic Patients Tr…

2014

Abstract Context: High-density lipoproteins (HDLs) from type 2 diabetic patients are unable to counteract the inhibitory effect of oxidized low-density lipoproteins (ox-LDLs) on vasorelaxation. We hypothesized that glitazones, which improve glycemic control and dyslipidemia, could correct this abnormality. Objectives and Design: We compared the ability of HDL from controls (n = 12) and from type 2 diabetic patients before and after 6 months of treatment with either rosiglitazone (n = 11) or pioglitazone (n = 8) to counteract the inhibitory effect of ox-LDL on vasodilatation of rabbit aorta rings. Results: Rosiglitazone induced a decrease in hemoglobin A1c (7.7% ± 1.1% vs 9.8% ± 1.0%, P = .0…

Malemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)BiochemistryRosiglitazonechemistry.chemical_compoundEndocrinologyHigh-density lipoproteinInternal medicineDiabetes mellitusmedicineAnimalsHumansHypoglycemic AgentsThiazolidinedioneAortaAgedDyslipidemiasPioglitazoneCholesterolbusiness.industryCholesterol HDLBiochemistry (medical)Middle Agedmedicine.diseaseLipoproteins LDLVasodilationEndocrinologyDiabetes Mellitus Type 2chemistryFemaleThiazolidinedionesEndothelium VascularRabbitsLipoproteins HDLRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.

2018

INTRODUCTION Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with monoclonal antibodies has complemented the armamentarium of lipid-lowering therapy (LLT) before the final step of commencing chronic lipoprotein apheresis (LA). Data are scarce on patients who, after escalation of LLT with PCSK9 antibodies, have commenced chronic LA or PCSK9 antibody treatment during ongoing long-term LA. PATIENTS AND METHODS In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutivel…

Malemedicine.medical_specialtymedicine.drug_classLipoproteinsHypercholesterolemia030204 cardiovascular system & hematologyMonoclonal antibodyGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEnzyme InhibitorsAdverse effectbiologybusiness.industryPCSK9PCSK9 InhibitorsAntibodies MonoclonalHematologyGeneral MedicineLipoprotein(a)Cholesterol LDLMiddle AgedAtherosclerosisCombined Modality TherapyLipidsDiscontinuationConcomitantCohortbiology.proteinBlood Component RemovalFemaleAntibodyProprotein Convertase 9business030215 immunologyLipoprotein(a)Journal of clinical apheresis
researchProduct

Rheopheresis in Patients with Critical Limb Ischemia--Results of an Open Label Prospective Pilot Trial

2005

Rheopheresis is a specifically designed application of double filtration plasmapheresis, for extracorporeal treatment of microcirculatory disorders. Safety and efficacy of Rheopheresis for wound healing and skin oxygenation were investigated in patients with critical limb ischemia. Twelve patients of Fontaine stage III-IV were treated with a series of 10 Rheopheresis sessions over 17 weeks. Transcutaneous oxygen pressure (tcpO(2)) and ankle-brachial index (ABI) were repeatedly determined to monitor the effects of the Rheopheresis treatment series on microcirculation and skin blood flow. Laboratory parameters of blood rheology were measured in addition to safety parameters and course of the …

Malemedicine.medical_specialtymedicine.medical_treatmentRheopheresisPilot ProjectsExtracorporealMicrocirculationIschemiamedicineHumansalpha-MacroglobulinsProspective StudiesProspective cohort studyAgedSkinWound Healingbusiness.industryFibrinogenProteinsCholesterol LDLPlasmapheresisHematologyCritical limb ischemiaOxygenationMiddle AgedSurgeryClinical trialTreatment OutcomeImmunoglobulin MLower ExtremityAmputationRegional Blood FlowNephrologyFemalemedicine.symptombusinessBlood Gas Monitoring TranscutaneousTherapeutic Apheresis and Dialysis
researchProduct

Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance charac…

2007

For many years dextran sulfate adsorption (DSA) treatment of separated plasma has been an established technology for low-density lipoprotein (LDL)-elimination. Recently a system for the treatment of whole blood based on DSA was introduced into clinical practice. To further characterize DSA treatment of whole blood, the performance characteristics of both DSA modalities were compared at two investigational sites with two alternative LDL apheresis systems being already in routine clinical use. In prospective cross-over design, DSA whole blood treatment was compared with a whole blood polyacrylate LDL adsorption system (DALI) in one study group. DSA for plasma treatment was compared with Lipid…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyAcrylic ResinsFibrinogenchemistry.chemical_compoundmedicineHumansWhole bloodbusiness.industryCholesterolDextran SulfateBlood Component RemovalFibrinogenHematologyGeneral MedicineCholesterol LDLHemoperfusionAtherosclerosisSurgerybody regionsApheresischemistryLDL apheresisBlood Component RemovalFemalebusinessFiltrationmedicine.drugLipoproteinJournal of clinical apheresis
researchProduct

Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database

2018

Background and objective: Obstructive sleep apnoea (OSA) and dyslipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and plasma lipid concentrations in patients enrolled in the European Sleep Apnea Database (ESADA) cohort. Methods: The cross-sectional analysis included 8592 patients without physician-diagnosed hyperlipidaemia or reported intake of a lipid-lowering drug (age 50.1 ± 12.7 years, 69.1% male, BMI: 30.8 ± 6.6 kg/m2, mean apnoea–hypopnoea index (AHI): 25.7 ± 25.9 events/h). The independent relationship between measures of OSA (AHI, oxygen desaturation index (ODI), mean and lowest oxygen saturation) and lipid profil…

MaleobesityDatabases Factualcholesterol dyslipidemia hypoxia obesity sleep apnoeaGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRisk FactorsHypolipidemic AgentsOxygen saturation (medicine)Sleep Apnea Obstructivemedicine.diagnostic_testSleep apneaMiddle AgedEuropeQuartileCardiovascular DiseasesCohortFemalelipids (amino acids peptides and proteins)AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansTriglyceridesDyslipidemiashypoxiaCholesterolbusiness.industryCholesterol HDLdyslipidemiacholesterolCholesterol LDLta3121medicine.diseaseObesitynervous system diseasesrespiratory tract diseasesCross-Sectional Studies030228 respiratory systemchemistryLipid profilebusinesssleep apnoea030217 neurology & neurosurgeryDyslipidemiaRespirology
researchProduct

Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression

2011

ObjectivesWe sought to assess the in vivo importance of scavenger receptor (SR)–mediated uptake of oxidized low-density lipoprotein (OxLDL) in atherogenesis and to test the efficacy of human antibody IK17-Fab or IK17 single-chain Fv fragment (IK17-scFv), which lacks immunologic properties of intact antibodies other than the ability to inhibit uptake of OxLDL by macrophages, to inhibit atherosclerosis.BackgroundThe unregulated uptake of OxLDL by macrophage SR contributes to foam cell formation, but the importance of this pathway in vivo is uncertain.MethodsCholesterol-fed low-density lipoprotein receptor knockout (LDLR−/−) mice were treated with intraperitoneal infusion of human IK17-Fab (2.…

MaleoxidationGenetic enhancementGreen Fluorescent Proteins030204 cardiovascular system & hematologymedicine.disease_causeArticleAdenoviridaeMice03 medical and health sciences0302 clinical medicineIn vivoAnimalsHumansantibodiesMedicineScavenger receptorReceptorImmunoglobulin Fragments030304 developmental biologyFoam cellHomeodomain ProteinsMice Knockout0303 health sciencesbiologybusiness.industryMacrophagesscavenger receptorsgene therapyRecombinant Proteins3. Good healthLipoproteins LDLMice Inbred C57BLAdenoviridaeReceptors LDLImmunologyDisease ProgressionCancer researchbiology.proteinlipids (amino acids peptides and proteins)atherosclerosisAntibodyCardiology and Cardiovascular MedicinebusinessFoam CellsLipoproteinJournal of the American College of Cardiology
researchProduct

Urinary Tartaric Acid, a Biomarker of Wine Intake, Correlates with Lower Total and LDL Cholesterol.

2021

Postmenopausal women are at higher risk of developing cardiovascular diseases due to changes in lipid profile and body fat, among others. The aim of this study was to evaluate the association of urinary tartaric acid, a biomarker of wine consumption, with anthropometric (weight, waist circumference, body mass index (BMI), and waist-to-height ratio), blood pressure, and biochemical variables (blood glucose and lipid profile) that may be affected during the menopausal transition. This sub-study of the PREDIMED (Prevención con Dieta Mediterránea) trial included a sample of 230 women aged 60–80 years with high cardiovascular risk at baseline. Urine samples were diluted and filtered, and tartari…

Mediterranean dietmenopauseWineUrinechemistry.chemical_compoundTX341-641TartratesRandomized Controlled Trials as TopicAged 80 and overNutrition and Dieteticsmedicine.diagnostic_testAnthropometryMiddle Agedlipid profilebody fatCholesterolCardiovascular DiseasesFemaleMenopausaPREDIMEDcardiovascular riskmedicine.medical_specialtyWaistAlcohol DrinkingÀcid tàrtricArticleInternal medicineMediterranean dietmedicineHumanspolyphenolsAgedWinebusiness.industryCholesterolMalalties cardiovascularsNutrition. Foods and food supplybiomarkersmediterranean dietCholesterol LDLEndocrinologyCross-Sectional StudieschemistryHeart Disease Risk Factorstartaric acidLipid profilebusinessBody mass indexFood ScienceLipoproteinNutrients
researchProduct

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct

Lipid profiling following intake of the Omega 3 fatty acid DHA identifies the peroxidized metabolites F-4-Neuroprostanes as the best predictors of at…

2014

International audience; The anti-atherogenic effects of omega 3 fatty acids, namely eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) are well recognized but the impact of dietary intake on bioactive lipid mediat or profiles remains unclear. Such a profiling effort may offer novel targets for future studies into the mechanism of action of omega 3 fatty acids. The present study aimed to determine the impact of DHA supplementation on the profiles of polyunsaturated fatty acids (PUFA) oxygenated metabolites and to investigate their contribution to therosclerosis prevention. A special emphasis was given to the non-enzymatic metabolites knowing the high susceptibility of DHA to free radical…

MouseBlood PressureCardiovascularBiochemistryMice0302 clinical medicineTandem Mass SpectrometryAetiologylcsh:Sciencechemistry.chemical_classificationLiquid0303 health sciences[CHIM.ORGA]Chemical Sciences/Organic chemistryFatty Acidsanti-atherogenic;omega 3 fatty acids;epa;dha;bioactive lipid;atherosclerosis;pufas;effects;molecularLipids3. Good healthFatty Acids UnsaturatedMedicinemedicine.medical_specialtyanti-atherogenicKnockoutAortic DiseasesMédecine humaine et pathologieGas Chromatography-Mass SpectrometryLDLDose-Response RelationshipLipid Mediators03 medical and health sciencesomega 3 fatty acids[ CHIM.ORGA ] Chemical Sciences/Organic chemistryacide gras n 3Complementary and Integrative HealtheffectsBiologybioactive lipidDose-Response Relationship DrugPreventionlcsh:RathéroscléroseEPALipid MetabolismPrevention of disease and conditionsmedicine.diseaseEndocrinologychemistryNeuroprostaneslcsh:QHuman health and pathologyBiomarkersand promotion of well-beinglcsh:Medicine030204 cardiovascular system & hematologymedicine.disease_causeOral and gastrointestinalHeart RateReceptorsBlood plasmaCluster Analysis2.1 Biological and endogenous factorsMice KnockoutUnsaturatedChromatographyMultidisciplinaryFatty liverAnimal ModelsDHALiverBiochemistryDocosahexaenoic acidlipids (amino acids peptides and proteins)DrugResearch ArticlePolyunsaturated fatty acidDocosahexaenoic AcidsClinical Research DesignGeneral Science & TechnologyBiologyModel OrganismsInternal medicinemedicineAnimalsNeuroprostanesAnimal Models of Diseasemolecular3.3 Nutrition and chemopreventionOmega 3 fatty acidNutrition030304 developmental biologyAnalysis of Varianceacide docosahexaénoiqueLipid metabolismAtherosclerosis[SDV.AEN] Life Sciences [q-bio]/Food and NutritionReceptors LDLPUFAs[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOxidative stressChromatography Liquid
researchProduct

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.

2021

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active roles in the onset and progression of CRC. Recently, small dense low-density lipoprotein (LDL) particles, a typical characteristic of diabetic dyslipidemia, emerged as another possible underlying link between T2DM and CRC. Growing evidence suggests that antidiabetic medications may have beneficial effects in CRC prevention. According to findings from a limited number of preclinical and clinical stud…

Oncologyendocrine system diseasesColorectal cancerComorbidityReview0302 clinical medicineinsulin resistanceEpidemiologyBiology (General)small dense LDLSpectroscopyglucagon-like peptide-1 receptor agonists0303 health sciencesIncidenceGeneral MedicineSmall dense LDL3. Good healthComputer Science ApplicationsLipoproteins LDLChemistry030220 oncology & carcinogenesismedicine.symptomColorectal Neoplasmsmedicine.medical_specialtyQH301-705.5InflammationCatalysisGlucagon-like peptide-1 receptor agonistsGlucagon-Like Peptide-1 ReceptorInorganic Chemistry03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIn patientPhysical and Theoretical ChemistryQD1-999Molecular BiologyAntidiabetic agents030304 developmental biologyInflammationbusiness.industryOrganic ChemistryType 2 Diabetes Mellitusnutritional and metabolic diseasesInsulin resistanceGlucagon-like peptide-1 receptor agonists Hyperglycemia Inflammation Insulin resistance Comorbidity Diabetes Mellitus Type 2 Glucagon-Like Peptide-1 Receptor Humans Hyperglycemia Hypoglycemic Agents Incidence Lipoproteins LDL Oxidative Stress Colorectal Neoplasms Small dense LDLmedicine.diseasedigestive system diseasesOxidative StressDiabetes Mellitus Type 2Oxidative stressinflammationHyperglycemiabusinessInternational journal of molecular sciences
researchProduct